Axovan: Very particular about GPCRs

G protein-coupled receptors have long been important, highly druggable targets. Axovan SA says its Axaddis and Axocell technologies allow it to perform accelerated, focused GPCR screening by skipping traditional target validation work and using GPCR-biased chemical libraries.

The Human Genome Project has revealed more than 1,500 GPCRs, according to CFO Philippe Dro. About 400 GPCRs are thought to be pharmaceutically relevant, but only 200 are functionally known and about

Read the full 692 word article

User Sign In

Article Purchase

This article may not be distributed to non-subscribers

PURCHASE THIS ARTICLE FOR LIMITED ONE-TIME DISTRIBUTION AND WEBSITE POSTING $995.00 USD

PURCHASE